ID    AEP18
PN    17BI
PL    17 
SO    Engineered Peptide (Synthetic) from Human Cathelicidin Antimicrobial Peptides
VL    Experimentally validated
PT    Chemically non-modified
MD     
XX
TO    Ebola virus [EBOV]
IC    IC50 ~ 3 microM
BT    Glycoprotein (GP).
TP    Viral entry.
XX
MN    The engineered peptide 17BI effectively inhibits Ebola virus infection by 
MN    targeting the endosomal entry step and disrupting cathepsin B-mediated processing 
MN    of the viral glycoprotein. Along with 17BI, the D-amino acid-containing 
MN    peptide GI-20d showed greater efficacy in blocking Ebola virus compared 
MN    to the parent peptide LL-37 and its derivatives. These peptides 
MN    were designed for enhanced biostability, making them resistant to intracellular 
MN    enzymatic degradation. The study underscores the potential of engineered antimicrobial 
MN    peptides like 17BI as a novel class of anti-Ebola therapeutics. 
XX
HA    Not available 
TC    The engineered peptide 17BI, along with other peptides, displayed lower 
TC    IC50 concentrations in HeLa cells compared to macrophages. This suggests 
TC    that the peptides were more toxic to HeLa cells than 
TC    macrophages. Peptide GI-20d showed the most favorable therapeutic window in 
TC    both HeLa cells and primary macrophages, with an IC50 of 
TC    0.99 mM in HeLa cells and 2.2 mM in macrophages. 
TC    Peptide 17BI also exhibited a favorable therapeutic window, with an 
TC    IC50 of 0.71 mM in HeLa cells and 5.6 mM 
TC    in macrophages. The study also reported TC50 values for the 
TC    peptides, indicating their cytotoxicity in both cell types. 
XX
XR    PubMed: 32252021
XR    RCSB PDB/PDBsum/PDBe/PDBj/PDBe-KB/MMDB: 2l5M_A
XR    UniProt: Not available
XX
SQ    SEQUENCE  
      GXKRLVQRLK DXLRNLV 
//